The results showed that the pathways in low-risk patients with ccRCC were mostly related to mast cell immunity and carcinoma, including the vascular endothelial growth factor (VEGF) signaling pathway, TGF beta signaling pathway, proteasome, cytokine receptor interaction, and RCC (Figure 9M). This evidence concerns the gene VEGFA and renal cell carcinoma.